On 29 May pimavanserin was approved by the US Food and Drug Administration as the first drug for treating hallucinations and delusions
New research published today has identified a vital new target in the search for treatments that can slow ageing, and could one day prevent Parkinson's.
In March the advisory panel for the US Food and Drug Administration approved a new drug for treating hallucinations and delusions in Parkinson's
California-based company, the International Stem Cell Corporation (ISCO), has announced the first clinical trials of a stem cell treatment for Parkinson's.
New research suggests that thinking difficulties may be more to blame than physical symptoms for speech problems in Parkinson's.
Researchers at the University of Bristol have discovered that a common dementia drug, rivastigmine, could reduce falls in people with Parkinson's.